Tuesday, 15 October 2013

Alzheimer's breakthrough hailed as 'turning point'

The discovery of the first chemical to prevent the death of brain tissue in a neurodegenerative disease has been hailed as the "turning point" in the fight against Alzheimer's disease. A drug that could be taken by patients still needs a lot more work to develop, but scientists say a resulting medicine could treat Alzheimer's, Parkinson's, Huntington's and other diseases.

In tests on mice, the Medical Research Council showed all brain cell death from prion disease could be prevented. Prof Roger Morris, from King's College London, said: "This finding, I suspect, will be judged by history as a turning point in the search for medicines to control and prevent Alzheimer's disease." He went on to say that a cure for Alzheimer's was not imminent but: "I'm very excited, it's the first proof in any living animal that you can delay neurodegeneration. The world won't change tomorrow, but this is a landmark study."

The research team at the Medical Research Council Toxicology Unit, based at the University of Leicester, focused on the natural defence mechanisms built into brain cells. When a virus hijacks a brain cell it leads to a build-up of viral proteins. Cells respond by shutting down almost all protein production in order to halt the spread of the virus. However, many neurodegenerative diseases involve the production of faulty or "misfolded" proteins. These activate the same defences, but with more severe consequences. The misfolded proteins linger and the brain cells shut down protein production for so long that they eventually starve themselves to death. This process is repeated in neurons throughout the brain, and can destroy movement, memory, or even kill, depending on the disease. Safely disrupting this process could treat a wide range of diseases, because it is thought to take place in many forms of neurodegeneration. The researchers halted neurodegeneration by using a compound which prevented those defence mechanisms kicking in.

The study showed mice with prion disease developed severe memory and movement problems, and all of these mice then died within 12 weeks. However, the mice that were given the compound showed no signs of their brain tissue wasting away. Side effects are an issue though, as the compound also acted on the pancreas, meaning the mice developed a mild form of diabetes and lost weight. Any drug given to humans would need to act only on the brain, but this gives scientists and drug companies a starting point which they can then improve on.

Dr Eric Karran, the director of research at the charity Alzheimer's Research UK, said: "Targeting a mechanism relevant to a number of neurodegenerative diseases could yield a single drug with wide-reaching benefits, but this compound is still at an early stage. It will be important for these findings to be repeated and tested in models of other neurodegenerative diseases, including Alzheimer's disease."

Jack

No comments:

Post a Comment